Clinical Trial Update: Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating ReFacto for Hemophilia A patients undergoing major surgery has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Refacto (Factor VIII, recombinant)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hemophilia A | Phase 4 | Status: COMPLETED